Drug-Resistant Tuberculosis Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Drug-Resistant Tuberculosis remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 87 matched trial records and 77 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07675954 | Levofloxacin + Bedaquiline Fumarate + Delamanid | Phase 3; Not yet recruiting | Seoul National University Hospital | South Africa | Favourable outcome at 12 months after treatment discontinuation (12 months after treatment discontinuation); Composite safety and tolerability endpoint (During treatment and up to 90 days after treatment discontinuation) | 2032-06-01 |
| NCT07638670 | Intervention not normalized | Not Applicable; Recruiting | Ningbo University | China | To establish a multi-immune pathway interaction network and composite biomarkers in mycobacterial infection thing (3 days before treatment and 2 months after treatment) | 2026-07-20 |
| ChiCTR2600121616 | Intervention not normalized | Phase 2; Recruiting | Shanghai Pulmonary Hospital | China | Sputum Acid-Fast Bacilli (AFB) Smear; Sputum Mycobacterium tuberculosis culture | 2028-05-31 |
| NCT07486024 | Bedaquiline Fumarate | Phase 3; Not yet recruiting | Assistance Publique des Hôpitaux de Paris SA | France | Effectiveness of BPaLM compared to conventional MDR-TB regimens (Day 0 to Month 18) | 2030-08-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis (Phase 1/2): the indexed record reports Participants Completing at Least 80% (≥90 of 112) of Assigned Study Drug Doses Within 18 Weeks = 14 participants; Participants Completing at Least 80% (≥90 of 112) of Assigned Study Drug Doses Within 18 Weeks = 11 participants; -.
- A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV (Phase 1/2): the indexed record reports -; Percentage of Participants With Adverse Events of ≥ Grade 3 Severity = 25.0 percentage of participants (95% Confidence Interval, 5.5 - 57.2); Percentage of Participants With Adverse Events of ≥ Grade 3 Severity = 18.2 percentage of participants (95% Confidence Interval, 2.3 - 51.8).
- Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial (Phase 4): the indexed record reports SAE = 33.0 %; SAE = -6.0 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Levofloxacin (Approved; Bacterial Top II x Bacterial top IV), Bedaquiline Fumarate (Approved; mycobacterial ATP synthase), Delamanid (Approved). Company & Deal Intelligence records identify sponsor context for Seoul National University Hospital, Ningbo University, Shanghai Pulmonary Hospital, Assistance Publique des Hôpitaux de Paris SA. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Drug-Resistant Tuberculosis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
